{"data":{"type":"company_profile","id":83653,"entity_id":"wefunder:company:83653","attributes":{"canonical_url":"https://wefunder.com/gerostate.alpha","generated_at":"2026-06-13T05:44:31Z","updated_at":"2026-06-13T05:00:36Z","entity_ids":{"company":"wefunder:company:83653","slug":"wefunder:company_slug:gerostate.alpha"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-13T05:44:31Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:44:31Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:44:31Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-06-03T14:15:43Z","as_of":"2026-06-13T05:44:31Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-06-03T14:15:43Z","as_of":"2026-06-13T05:44:31Z","confidence":"medium"}}},"company":{"id":83653,"entity_id":"wefunder:company:83653","slug":"gerostate.alpha","name":"Gerostate Alpha (YC S18)","tagline":"A pharmaceutical company dedicated to treating aging and age-related disease","elevator_pitch":"Gerostate Alpha is a new pharmaceutical company dedicated to treating aging and age-related disease. Incubating at the Buck Institute for Research on Aging, we develop breakthrough pharmaceuticals through proprietary innovations to mitigate and reduce the effects of aging.","location":"San Francisco, CA","website":"https://www.gerostatealpha.com/","total_amount_raised":564622,"total_investors":465,"is_funded":true,"is_active":true,"quality_score":4,"related_urls":["https://wefunder.com/gerostate.alpha","https://www.gerostatealpha.com/"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/83653/xxl_cropped_GSAFounders_Image.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/83653/large_cropped_Screen_Shot_2021-03-29_at_6.45.14_PM.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/83653/standard_cropped_GSAFounders_Image.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/83653/standard_cropped_GSAFounders_Image.jpg","profile_video_url":"https://wefunder.wistia.com/medias/83cbh1mnki"},"links":{"company_url":"https://www.gerostatealpha.com/"},"highlights":[],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"💵 $2.1M raised in initial seed round, at $15M valuation cap"},{"index":2,"claim_id":"claim-fact-2","value":"🧬 Team at the forefront of aging research for decades, collectively authoring 200+ papers"},{"index":3,"claim_id":"claim-fact-3","value":"💪 Our platform delivers drug candidates to slow aging at a success rate of 20%"},{"index":4,"claim_id":"claim-fact-4","value":"🐭 Funds will be used to test our candidates in aging mice"},{"index":5,"claim_id":"claim-fact-5","value":"🧳 Executive chairman was former CEO of major pharma company, Sangamo Therapeutics"}],"team":[{"id":1607734,"entity_id":"wefunder:company_role:1607734","user_entity_id":"wefunder:user:1403969","role":"founder","name":"Simon Melov","title":"CEO","bio":"PhD; Professor at Buck Institute for Research on Aging \u0026amp; CEO of Gerostate Alpha","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1607734/square_cropped_simon.jpg?1617340704","profile_url":"https://wefunder.com/simonmelov","personal_url":"http://www.gerostatealpha.com","linkedin_url":"https://www.linkedin.com/in/simon-melov-92040016b/","related_urls":["https://wefunder.com/simonmelov","http://www.gerostatealpha.com"]},{"id":1607736,"entity_id":"wefunder:company_role:1607736","user_entity_id":"wefunder:user:1403985","role":"founder","name":"Mark S Lucanic","title":"CTO","bio":"PhD; Expert in small molecule and genetic screens including significant experience with high throughput technologies, and has utilized simple model organisms to explore pharmacological extension of lifespan.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1607736/square_cropped_Screen_Shot_2021-03-29_at_6.40.55_PM.jpg?1617525302","profile_url":"https://wefunder.com/markslucanic","personal_url":"http://www.gerostatealpha.com","related_urls":["https://wefunder.com/markslucanic","http://www.gerostatealpha.com"]},{"id":1607738,"entity_id":"wefunder:company_role:1607738","role":"founder","name":"Gordon Lithgow","title":"Professor, Vice President Buck Institute","bio":"PhD; Chief Academic Officer at the Buck Institute for Research on Aging and specializes in the properties of small molecules to extend lifespan, having been internationally recognized for his work on aging with numerous awards and prizes.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1607738/square_cropped_Screen_Shot_2021-03-29_at_6.41.02_PM.jpg?1617318129","related_urls":[]}],"featured_investors":[{"id":5616,"entity_id":"wefunder:company_investor_profile:5616","investor_profile_id":1445152,"investor_profile_entity_id":"wefunder:investor_profile:1445152","subject_entity_id":"wefunder:user:1933365","name":"C S","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6NTI1MjczLCJwdXIiOiJibG9iX2lkIn19--c63aca5ee4864be413a4b8721ac1890ba9fc7f5d/filename","profile_url":"https://wefunder.com/cs21","investment_total":25000,"investment_info":"Invested $25,000 this round","is_lead_investor":true,"related_urls":["https://wefunder.com/cs21"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":20,"featured_investors":1,"faq_entries":5},"active_fundraises":[{"id":51457,"entity_id":"wefunder:fundraise:51457","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"funding_started_at":"2021-10-05T01:03:13Z","funding_closed_at":"2021-11-16T05:01:20Z","auto_close_at":"2021-11-16T04:59:59Z"},{"id":51458,"entity_id":"wefunder:fundraise:51458","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"equity","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"funding_started_at":"2021-09-06T18:04:40Z"},{"id":44338,"entity_id":"wefunder:fundraise:44338","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"funding_started_at":"2021-07-20T01:11:49Z","funding_closed_at":"2021-08-10T05:02:32Z","auto_close_at":"2021-08-10T03:59:59Z"},{"id":44339,"entity_id":"wefunder:fundraise:44339","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"equity","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":500000.0,"funding_started_at":"2021-03-30T01:52:51Z"}],"latest_fundraise":{"id":51457,"entity_id":"wefunder:fundraise:51457","state":"successful","offering_type":"4(a)(6)","structure":"safe","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2021-10-05T01:03:13Z","funding_closed_at":"2021-11-16T05:01:20Z","terms":{"eb":"$18M","nb":"$20M","txt":"valuation cap"}},"recent_posts":[],"q_and_a":[{"id":145576,"entity_id":"wefunder:comment:145576","question":"This is at bottom of page so that being said nothing invested today will be an investment but a donation correct ??? When will scheduke c be filed and when can I get in pre ipo TThat's what u want to know and where do or who do i talk to to make that happen. Wefunder means Wefunder Inc and its wholly owned subsidiaries: Wefunder Advisors LLC and Wefunder Portal LLC. This page is hosted by Wefunder Portal LLC. Gerostate Alpha (YC S18) is testing the waters to evaluate investor interest. No money or other consideration is being solicited; if sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and, then, only through Wefunder. Any indication of interest has no obligation or commitment of any kind","author_name":"Jerry Egger","votes":2,"created_at":"2021-04-28T15:52:30Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-145576","answers":[{"id":146997,"entity_id":"wefunder:comment:146997","answer":"I believe that jargon indicates that we have yet to file our form C. I think the way it works is that the money is held in escrow until we complete our filing of the necessary paperwork to raise through this mechanism. We cannot accept the investment until Form C is filed. There no donations here, any money we accept through Wefunder will be an investment.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-05-03T22:53:41Z"}]},{"id":178750,"entity_id":"wefunder:comment:178750","question":"I listened to your video and read what I could on your website. Does your treatment look to cure or slow parts of aging where a beneficial byproduct will be reduced Alzheimer's cases (for example)? Or, does your research and test look to slow aging which will kill or prohibit diseases such as Alzheimer's? More or less, does this just delay someone from getting Alzheimer's which could make their situation worse? If this doesn't delay the inevitable of Alzheimer's, then I'd invest.","author_name":"Matt King","votes":1,"created_at":"2021-11-11T00:45:50Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-178750","answers":[{"id":178941,"entity_id":"wefunder:comment:178941","answer":"This is a hard question to answer definitively in the absence of cures of course. However, in model systems where we can routinely extend lifespan, overall, health span is also increased. Hence, the available data suggests if you can extend lifespan, you should also extend health span. Alas, we do not have human data yet, but the animal model data in this regard is very encouraging!","author_name":"Simon Melov","votes":0,"created_at":"2021-11-11T23:29:12Z"}]},{"id":171018,"entity_id":"wefunder:comment:171018","question":"When will the investment terms be decided?","author_name":"Josh S","votes":1,"created_at":"2021-09-24T01:26:40Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-171018","answers":[{"id":171514,"entity_id":"wefunder:comment:171514","answer":"Thanks for the interest, terms will be listed when the Wefunder campaign formally launches. We expect to offer SAFEs at a post money valuation of 20M. We also expect to offer better terms for the first investors in the round, stay tuned.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-09-28T17:13:49Z"}]},{"id":161208,"entity_id":"wefunder:comment:161208","question":"Do you intend to pay a dividend (post-SAFE conversion)?","author_name":"Craig J. Vom Lehn","votes":1,"created_at":"2021-08-03T16:30:13Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-161208","answers":[{"id":161571,"entity_id":"wefunder:comment:161571","answer":"We like the idea of dividends. As you are no doubt aware, payment of dividends is contingent on many factors. At this point, we cannot predict those factors with any certainty. However, if conditions are right in the future, and our company has a strong rationale for paying dividends once we have a mature product pipeline, we would strongly consider it.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-08-04T21:04:05Z"}]},{"id":150037,"entity_id":"wefunder:comment:150037","question":"Good morning, Congrats on your success so far! Just two questions: what is the maximum amount you're looking to raise in this round? And does the round have a closing date? Thanks!","author_name":"Brian Eller","votes":1,"created_at":"2021-05-21T14:02:22Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-150037","answers":[{"id":154406,"entity_id":"wefunder:comment:154406","answer":"We are using the Wefunder portal to “test the waters” for raising capital for development of aging therapeutics. To that end, we do not have an upper limit, and are excited to see how far it goes. Regarding closing, we will be making an announcement about that shortly.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-06-22T15:39:06Z"}]},{"id":148703,"entity_id":"wefunder:comment:148703","question":"I have just invested in Gerostate Alpha EUR 100. I transfered EUR 100 to your bank account in March and came to an understanding with your staff that these funds will be used for the next investment. What shall I do to finish the investment. Regards. Silvia Vybiralova{Britkova)","author_name":"Silvia Vybiralova","votes":1,"created_at":"2021-05-13T16:31:00Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-148703","answers":[{"id":149723,"entity_id":"wefunder:comment:149723","answer":"Hi Silvia. Thanks for your investment. Wefunder administers this portal, please contact them directly with your questions related to fund transfers.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-05-19T23:17:48Z"}]},{"id":147711,"entity_id":"wefunder:comment:147711","question":"Hi Dr. Lucanic, Congratulations on getting this kickstarted, I'm looking forward to Gerostate Alpha's future progress and developments! As someone who has a keen interest in getting involved within the field of longevity, do you have any advice on how I can get my foot in the door with a non-traditional background? My experience is primarily in quantitative finance (programming, statistics, etc), but I always have been intrigued on how I could perhaps transition some of these skillsets into medical research (bioinformatics, computational bio, AI driven applications). Do you have any recommendations on how I can best make the career change? I'd like to think I can pick up some of the prerequisite knowledge fast and really start contributing towards this endeavor. Even if it's non-scientific at first, I can probably still help out on the operational side/streamlining some automation tasks or even data scraping and really improve efficiencies in most labs. I'd be willing to work free of charge if there are any \"openings\" you know of or if you can point me in the right direction!","author_name":"Mark Shin","votes":1,"created_at":"2021-05-07T14:08:28Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-147711","answers":[{"id":149722,"entity_id":"wefunder:comment:149722","answer":"Hi Mark. Thanks for the interest. It is difficult for me to say how you can get involved, without knowing more about your skill set. Please contact me directly if you would like to have a detailed chat. Certainly, investing in promising companies is a good start. You may also want to consider contacting academic groups to offer your services as a means to gain experience.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-05-19T23:17:41Z"}]},{"id":143253,"entity_id":"wefunder:comment:143253","question":"Hi Dr. Lucanic. Congratulations on the funding campaign here on Wefunder. I'd like to ask how your solution to treating age-related diseases compares to that of under development by Samumed (now Biosplice), who raised $438 million in 2018 for a valuation of $12 billion. Even with such funding, they admit that \" the company is some years away from delivering a marketable product aimed at one of the aging processes\". When do you think you'll be able to bring a viable product to the market? Also, I'd appreciate it if you could elaborate on the Estimated future funding it would necessitate to get there. Thanks in advance for your time and response.","author_name":"Ozzy Akay","votes":1,"created_at":"2021-04-19T21:24:42Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-143253","answers":[{"id":143483,"entity_id":"wefunder:comment:143483","answer":"Hello Dr. Akay. We are quite different, in part because we focus directly on aging, instead of on certain candidate pathways (such as the wingless/int pathway) or a single processes (such as cellular senescence), that have been implicated in driving aging. Our main thrust is in searching chemical space for structures that effectively modulate aging itself. We expect this approach will lead to the identification of novel pathways (and possibly new biology!) that modulates aging, as well as identifying critical new drivers of existing pathways. While we are confident in our scientific methodology ultimately leading to novel discoveries, the business of drug development is indeed daunting. The estimated cost of getting a new drug to market is often cited as being higher than a billion dollars. We are currently at the later stages of platform development and are entering into significant preclinical studies of potential drug leads. We do not expect to enter clinical studies with novel drug leads for at least 18 months. That being said, we expect to generate revenue and contribute to human health through mechanisms beyond in house development of novel drugs. We plan to license out some of our discoveries in the interim. Additionally, we are using our platform to explore the potential effectiveness of known drugs, natural products and natural product mixtures. While we do not expect the potency of those types of treatments to rival our novel drug development program, they represent a quicker path to commercialization.","author_name":"Mark S Lucanic","votes":2,"created_at":"2021-04-20T19:46:23Z"}]},{"id":179968,"entity_id":"wefunder:comment:179968","question":"Are you likely to have another fundraising round?","author_name":"John Turner","votes":0,"created_at":"2021-11-19T02:51:59Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-179968","answers":[]},{"id":178999,"entity_id":"wefunder:comment:178999","question":"Hi, I actually invested $1000 already, about 3 weeks ago but I have not received any confirmation or notification regarding it yet. Apart from the charge appearing on my card bill. Could you please send a receipt at least? Thank you, David Charlton","author_name":"David Charlton","votes":0,"created_at":"2021-11-12T07:37:46Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-178999","answers":[]},{"id":172976,"entity_id":"wefunder:comment:172976","question":"What brings you back to WeFunder? What (if anything) has changed since the last raise?","author_name":"Amit Sinha","votes":0,"created_at":"2021-10-06T18:19:10Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-172976","answers":[{"id":173527,"entity_id":"wefunder:comment:173527","answer":"Hi Amit, we've had some exciting development in our pipeline (see todays post), and considerable new investor interest. The combination of these two factors convinced us to allow more investors the opportunity to participate in GSAs growth.","author_name":"Simon Melov","votes":1,"created_at":"2021-10-10T21:09:36Z"}]},{"id":159055,"entity_id":"wefunder:comment:159055","question":"Hello my friends, what are you doing that is different than David Sinclair? I've been on his treatment plan sense his book came out. I feel great and have tons of energy. Thank you...","author_name":"Peter Woods","votes":0,"created_at":"2021-07-21T08:41:47Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-159055","answers":[{"id":171963,"entity_id":"wefunder:comment:171963","answer":"Davids approach is fundamentally different, and relies on natural supplements. We believe the major pathways modulating aging have yet to be discovered, and we hope our platform will reveal novel mechanism which can be pharmacologically targeted.","author_name":"Simon Melov","votes":0,"created_at":"2021-09-30T21:36:38Z"}]},{"id":153899,"entity_id":"wefunder:comment:153899","question":"As a long suffering shareholder in BioTime, now Lineage Cell Therapeutics and AgeX, I can appreciate the often decades long lead times to these discoveries. When do you anticipate a Form C to be filed?","author_name":"Rod Salvador","votes":0,"created_at":"2021-06-16T20:16:13Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-153899","answers":[{"id":154408,"entity_id":"wefunder:comment:154408","answer":"We anticipate filing Form C with the SEC in early July 2021.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-06-22T15:39:54Z"}]},{"id":150047,"entity_id":"wefunder:comment:150047","question":"Also, could you go into a bit more detail about your business development strategy? Specifically, what you mean by \"novel small molecules,\" \"off-patent approved drugs,\" and \"natural products\"?","author_name":"Brian Eller","votes":0,"created_at":"2021-05-21T14:30:13Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-150047","answers":[{"id":154407,"entity_id":"wefunder:comment:154407","answer":"These types of chemicals have clear differences in their paths to Market. We consider natural products to be chemicals produced in nature. Some of these are considered GRAS (generally regarded as safe) by the FDA and have a relatively low bar for commercial sales. Off-patent approved drugs are commercially produced drugs, that have previously been approved by a governmental regulatory body for use in humans. We would be pursuing novel uses for these drugs and the regulatory approval process for such repurposed drugs is simpler than it would be for new drugs. Finally, novel small molecules are chemicals that lack known biological activity and require major development, testing and approval for commercialization. We consider this last group to have the most potential for our success.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-06-22T15:39:33Z"}]},{"id":149159,"entity_id":"wefunder:comment:149159","question":"Could you please give an example of one of the molecules that you are researching? I see N1, is that N1-methyl-2- pyridone-5-carboxamide // N1-methyl-4-pyridone-3-carboxamide?","author_name":"Patrick Spaulding Ryan, PhD","votes":0,"created_at":"2021-05-16T06:01:42Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-149159","answers":[{"id":149724,"entity_id":"wefunder:comment:149724","answer":"Hi Patrick. We cannot discuss structural specifics of the candidates that we are developing as they are novel, and are in the process of being evaluated as future intellectual property of Gerostate.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-05-19T23:18:00Z"}]},{"id":147114,"entity_id":"wefunder:comment:147114","question":"So your progress has been since the last funding round that you have seen that it slows aging at a rate of 20% and now you want to do human trials? From this I understand that it means if someone were to take these every day they'd live 20% longer? So instead of 100 years, they'd live 120 years on average? Is that correct? How come no increase in valuation since the last one? Were there any sideeffects? Do you use any AI-related method to find possible drug candidates?","author_name":"Tal Charnes","votes":0,"created_at":"2021-05-04T12:50:03Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-147114","answers":[{"id":147576,"entity_id":"wefunder:comment:147576","answer":"Thanks for your interest. We are not currently in human trials. To identify high value drug candidates, we are using a variety of models including pre-clinical models such as cell culture (where we assess the toxicity, effects on viability and probe mechanistic actions of our candidates), invertebrates (where we have observed the large % increase in lifespans after treatment with our candidates), and vertebrates where we test our candidates for effects on rates of aging in distinct tissues and organs. We do a lot of triaging of molecules and generally discard specific candidates when side effects are observed. Going forward, we will adjust our valuation based on progress and market value. With regards to machine learning or AI, we are familiar with the methodology, and have previously partnered with companies that do the sort of work you describe.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-05-06T17:48:33Z"}]},{"id":143120,"entity_id":"wefunder:comment:143120","question":"How much time do the founders have available to work for Gerostate Alpha? Are there any (full time) employees next to the founders?","author_name":"Alexander Groenen","votes":0,"created_at":"2021-04-19T14:10:58Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-143120","answers":[{"id":143481,"entity_id":"wefunder:comment:143481","answer":"One of the founders is full time, the other two founders currently devote part of their time to Gerostate. As Gerostate Alpha builds we expect more of their time will be committed to its development and function. Most of our labor currently comes from independent contractors or organizations that we employ to complete our milestones. Going forward, we expect to hire additional full time team members with skill and expertise in specific Chemistry and Biology domains that correspond to key inflection points in Gerostate’s future growth trajectory.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-04-20T19:42:42Z"}]},{"id":142398,"entity_id":"wefunder:comment:142398","question":"Hello As someone that knows a thing or two about human physiology/anatomy, and having in consideration that more than likely you will need 1 - 3 compounds to make a fully body regeneration, why go with a mouse model and not a pig? Is it just an economic decision? Best regards, Miguel Costa","author_name":"Miguel Costa","votes":0,"created_at":"2021-04-16T00:59:47Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-142398","answers":[{"id":143479,"entity_id":"wefunder:comment:143479","answer":"Thanks for your interest. As you suggest, we focus on aging mice for our initial mammalian studies in part because they are the most economical and accessible of the established pre-clinical models.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-04-20T19:41:47Z"}]},{"id":142076,"entity_id":"wefunder:comment:142076","question":"Do you base your research on any theory of aging? Thoughts on Mikhail Blagosklonny quasi-programmed hyperfunction theory of aging?","author_name":"Samuel Lewis","votes":0,"created_at":"2021-04-14T22:28:06Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-142076","answers":[{"id":142293,"entity_id":"wefunder:comment:142293","answer":"We like the model to explain aspects of why aging occurs in organisms. in many ways, this model is indistinguishable from a well regarded classic model of aging, known as antagonistic pleiotropy (AP). While supported by experimental evidence, the theory by itself is generally regarded as being insufficient to comprehensively explain lifespan and or aging. AP though is considered an important part of what is a certainly a complex phenomenon.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-04-15T17:53:53Z"}]},{"id":141463,"entity_id":"wefunder:comment:141463","question":"Hi, I just invested $100 in your company but I am very confused, lol,,, how many shares did I buy?,,, What's the meaning of you guys going public?,,, Are you going to have a ticker symbol?,,, I been trying to get a hold of someone at Wefunder to get all this info but nobody answers the phone calls and nobody responds to my emails.,, So please let me know,,, Thank you,,, Vartan Vartanians","author_name":"Vartan VARTANIANS","votes":0,"created_at":"2021-04-13T13:48:06Z","canonical_url":"https://wefunder.com/gerostate.alpha#question-141463","answers":[{"id":142294,"entity_id":"wefunder:comment:142294","answer":"Thanks for your investment. We are not currently a public company and so we are not traded or defined by a symbol on any exchange. I suggest reading about investment terms and mechanisms in order to better understand how the wefunder program works. Wefunder has helpful FAQ and 'learn more' sections as a starting point.","author_name":"Mark S Lucanic","votes":0,"created_at":"2021-04-15T17:55:31Z"}]}],"faq":[{"question":"Hi, I just invested $100 in your company but I am very confused, lol,,, how many shares did I buy?,,, What's the meaning of you guys going public?,,, Are you going to have a ticker symbol?,,, I been trying to get a hold of someone at Wefunder to get all this info but nobody an...","answer":"Thanks for your investment. We are not currently a public company and so we are not traded or defined by a symbol on any exchange. I suggest reading about investment terms and mechanisms in order to better understand how the wefunder program works. Wefunder has helpful FAQ and 'learn more' sections as a starting point."},{"question":"Do you base your research on any theory of aging? Thoughts on Mikhail Blagosklonny quasi-programmed hyperfunction theory of aging?","answer":"We like the model to explain aspects of why aging occurs in organisms. in many ways, this model is indistinguishable from a well regarded classic model of aging, known as antagonistic pleiotropy (AP). While supported by experimental evidence, the theory by itself is generally regarded as being insufficient to comprehensively explain lifespan and or aging. AP though is considered an important part of what is a certainly a complex phenomenon."},{"question":"Hello As someone that knows a thing or two about human physiology/anatomy, and having in consideration that more than likely you will need 1 - 3 compounds to make a fully body regeneration, why go with a mouse model and not a pig? Is it just an economic decision? Best regards,...","answer":"Thanks for your interest. As you suggest, we focus on aging mice for our initial mammalian studies in part because they are the most economical and accessible of the established pre-clinical models."},{"question":"How much time do the founders have available to work for Gerostate Alpha? Are there any (full time) employees next to the founders?","answer":"One of the founders is full time, the other two founders currently devote part of their time to Gerostate. As Gerostate Alpha builds we expect more of their time will be committed to its development and function. Most of our labor currently comes from independent contractors or organizations that we employ to complete our milestones. Going forward, we expect to hire additional full time team members with skill and expertise in specific Chemistry and Biology domains that correspond to key infl..."},{"question":"Hi Dr. Lucanic. Congratulations on the funding campaign here on Wefunder. I'd like to ask how your solution to treating age-related diseases compares to that of under development by Samumed (now Biosplice), who raised $438 million in 2018 for a valuation of $12 billion. Even w...","answer":"Hello Dr. Akay. We are quite different, in part because we focus directly on aging, instead of on certain candidate pathways (such as the wingless/int pathway) or a single processes (such as cellular senescence), that have been implicated in driving aging. Our main thrust is in searching chemical space for structures that effectively modulate aging itself. We expect this approach will lead to the identification of novel pathways (and possibly new biology!) that modulates aging, as well as ide..."}]}}}